today announced that it has completed successfully and reached a separate agreement with the U http://suhagrastore.com .S. Food and Drug Administration under the Special Protocol Assessment process for its LibiGel program in the treatment of female sexual dysfunction , specifically hypoactive sexual desire disorder in ‘natural’women in menopause. Previously, BioSante received an SPA for LibiGel use in ‘surgically ‘women during menopause. ‘Aside from being another major milestone naturally BioSante, receiving a second SPA for naturally menopausal women in a significant development for the entire FSD category,’said Stephen M. BioSante’s president & CEO. ‘This action is confirmed by the FDA again FDA ‘s position that FSD and HSDD are true diagnosable conditions that women experience, with measurable endpoints, will be evaluated and may earn the therapeutic options. It is important that the FDA now officially this position both operationally and said of course women in the menopause. ‘.
BIO The 2008 exhibition will be 36 country and regional pavilions showing a common area for companies in the region. For the first time pavilions for 2008 include South Africa, Brazil, Argentina and Portugal. The top ten international pavilions in terms of size include Canada, Germany, France, the United Kingdom, Scandinavia, Italy, Spain and Australia.
Is often these patients should be have a significant risk to of VTE due to persistent immobility, rapid fire or active cancer requires chemotherapy. Caprini also noted that of the bleeding of bleeding perform an insufficient use of prophylactic resources, such as aspirin and foot pumps, and thus morbidity and mortality rates morbidity and mortality out of VTE.